Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium.
BACKGROUND
The regulation of angiotensin II receptors and the two major subtypes (AT1 and AT2) in chronically failing human ventricular myocardium has not been previously examined.


RESULTS
Angiotensin II receptors were measured by saturation binding of 125I-[Sar1,Ile8]angiotensin II in crude membranes from nonfailing (n = 19) and failing human left ventricles with idiopathic dilated cardiomyopathy (IDC; n = 31) or ischemic cardiomyopathy (ISC; n = 21) and membranes from a limited number of right ventricles in each category. The AT1 and AT2 fractions were determined by use of an AT1-selective antagonist, losartan. beta-Adrenergic receptors were also measured by binding of 125I-iodocyanopindolol with the beta 1 and beta 2 fractions determined by use of a beta 1-selective antagonist, CGP20712A, AT1 but not AT2 density was significantly decreased in the combined (IDC + ISC) failing left ventricles (nonfailing: AT1 4.66 +/- 0.48, AT2 2.73 +/- 0.39; failing: AT1 3.20 +/- 0.29, AT2 2.70 +/- 0.33 fmol/mg protein; mean +/- SE). The decrease in AT1 density was greater in the IDC than in the ISC left ventricles (IDC: 2.73 +/- 0.40, P < .01; ISC: 3.89 +/- 0.39 fmol/mg protein, P = NS versus nonfailing). beta 1 but not beta 2 density was decreased in the failing left ventricles. AT1 density was correlated with beta 1 density in all left ventricles (r = .43). AT1 density was also decreased in IDC right ventricles. In situ reverse transcription-polymerase chain reaction in sections of nonfailing and failing ventricles indicated that AT1 mRNA was present in both myocytes and nonmyocytes.


CONCLUSIONS
AT1 receptors are selectively downregulated in failing human ventricles, similar to the selective downregulation of beta 1 receptors. The relative lack of AT1 downregulation in ISC hearts may be related to differences in the degree of ventricular dysfunction.
Asano
K
K
Temple Hoyne Buell Heart Center Research Laboratories, Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA.
Dutcher
D L
DL
Port
J D
JD
Minobe
W A
WA
Tremmel
K D
KD
Roden
R L
RL
Bohlmeyer
T J
TJ
Bush
E W
EW
Jenkin
M J
MJ
Abraham
W T
WT
Raynolds
M V
MV
Zisman
L S
LS
Perryman
M B
MB
Bristow
M R
MR
D000328:Adult; D000804:Angiotensin II / Q000031:analogs & derivatives / Q000378:metabolism; D002311:Cardiomyopathy, Dilated / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D015536:Down-Regulation; D005260:Female; D006333:Heart Failure / Q000378:metabolism* / Q000473:pathology; D006352:Heart Ventricles; D006801:Humans; D007700:Kinetics; D008297:Male; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D016133:Polymerase Chain Reaction; D011869:Radioligand Assay; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D018342:Receptors, Adrenergic, beta-1 / Q000378:metabolism; D018343:Receptors, Adrenergic, beta-2 / Q000378:metabolism; D011945:Receptors, Angiotensin / Q000096:biosynthesis*; D012016:Reference Values
D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D018342:Receptors, Adrenergic, beta-1; D018343:Receptors, Adrenergic, beta-2; D011945:Receptors, Angiotensin; D000804:Angiotensin II; C009210:sarleucin